JG - JA DME

Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes.

The JG modifier was established by CMS and is required for 340B participating entities for separately payable Part B drugs or biologicals acquired under the 340B Drug Pricing Program

• Required for dates of service on/after January 1, 2024
• Discontinued effective December 31, 2024
• Suppliers may transition from use of the JG modifier to the TB modifier effective immediately for dates of service on/after January 1, 2024

Resources

• FAQ: Medicare-FFS Program Billing 340B Modifiers under the Hospital Outpatient Prospective Payment System (OPPS) (cms.gov)
• 340B Drug Pricing Program | HRSA
• Inflation Rebates in Medicare (cms.gov)
• MLN4800856 - Medicare Part B Inflation Rebate Guidance: Use of the 340B Modifier (cms.gov)